Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.38 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22800230 | 0.84 | CYP4F2 (0.39) | MAPTKMT2AHTTCYP26A1HPGD | |
| SCHEMBL22800227 | 0.84 | CYP4F2 (0.39) | MAPTKMT2AHTTCYP26A1HPGD | |
| SCHEMBL22799768 | 0.84 | CYP4F2 (0.39) | MAPTKMT2AHTTCYP26A1HPGD | |
| SCHEMBL22800090 | 0.73 | KDM4E (0.44) | MAPTDAGLAHPGDCYP3A4 | |
| SCHEMBL22800062 | 0.69 | DAGLA (0.36) | DAGLA | |
| SCHEMBL28859968 | 0.68 | TAS1R3 (0.46) | MAPTKMT2ACYP26A1HPGD | |
| SCHEMBL22799765 | 0.67 | MAPT (0.35) | MAPT | |
| SCHEMBL15663043 | 0.67 | ALDH1A1 (0.49) | MAPTHPGD | |
| SCHEMBL15663046 | 0.67 | ALDH1A1 (0.49) | MAPTHPGD | |
| SCHEMBL12308107 | 0.67 | KMT2A (0.44) | MAPTCAPN1MAPK1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | Knobbe, Martens, Olson & Bear, LLP | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN2, CAPN1 | MAPT 472/4885CAPN1 3/4885DAGLA 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.